425: SEC Declares Registration Statement Effective for Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Merger

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that the SEC has declared their Form S-4 registration statement effective, paving the way for a shareholder vote on their proposed business combination.

Summary

• Helix Acquisition Corp. II (HLXB) and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (BBOT) jointly announced that the Registration Statement on Form S-4, related to their previously announced business combination, has been declared effective by the U.S. Securities and Exchange Commission (SEC).
• An Extraordinary General Meeting of Helix shareholders is scheduled for August 4, 2025, to consider and vote on the Business Combination.
• The definitive proxy statement/prospectus for the meeting will be mailed to Helix's shareholders of record as of June 30, 2025.
• The parties anticipate the Business Combination will close in August 2025, contingent upon the satisfaction or waiver of closing conditions.
• Upon the closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics (PubCo).
• BBOT is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for RAS and PI3K malignancies.
• Helix Acquisition Corp. II is a special purpose acquisition company (SPAC) sponsored by Cormorant Asset Management, which raised $184 million in its initial public offering on February 9, 2024.

Sentiment

Score: 7

Explanation: The announcement of the S-4 effectiveness and the scheduling of the shareholder meeting are positive procedural steps towards completing the merger, indicating progress. However, it's a procedural update rather than a new financial or clinical milestone, so the sentiment is positive but not exceptionally high.

Positives

• The SEC declared the Form S-4 Registration Statement effective, which is a critical procedural step towards completing the business combination.
• A definitive date of August 4, 2025, has been set for the Extraordinary General Meeting of Helix shareholders, providing clarity on the merger timeline.
• The anticipated closing of the Business Combination in August 2025 indicates steady progress towards the merger's completion.
• BBOT's focus on RAS and PI3K malignancies targets two of the most prevalent oncogenes in human tumors, suggesting a significant market opportunity for its product candidates.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Inability of the parties to successfully or timely enter into definitive agreements or consummate the business combination.
• Risk that regulatory approvals are not obtained, are delayed, or are subject to unanticipated conditions (e.g., SEC statements or enforcements relating to SPACs) that could adversely affect the combined company or the expected benefits.
• Risk that the approval of Helix's shareholders or any other condition to closing is not obtained.
• Failure to realize the anticipated benefits of the business combination.
• Risks relating to any legal proceedings that may be instituted against Helix, the combined company, or others following the announcement of the business combination.
• Uncertainty of the projected financial information with respect to BBOT and the combined company.
• Risks related to the approval of BBOT's product candidates and the timing of expected regulatory and business milestones.
• Ability to negotiate definitive contractual arrangements with potential customers.
• Impact of competitive product candidates.
• Ability to obtain sufficient supply of materials.
• Global economic and political conditions.
• Effects of competition on BBOT's future business.
• Amount of redemption requests made by Helix's public shareholders.
• Uncertainty regarding outcomes of BBOT's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates.
• Risks associated with BBOT's efforts to commercialize its product candidates.
• BBOT's ability to maintain its existing agreements with third parties and to negotiate and enter into new definitive agreements on favorable terms, if at all.
• Intellectual property-related claims.
• BBOT's ability to attract and retain qualified personnel.
• BBOT's ability to source the raw materials for its product candidates.

Future Outlook

The business combination is anticipated to close in August 2025, subject to shareholder approval and other closing conditions. BridgeBio Oncology Therapeutics expects to continue its product development activities, including the progress and results of the ONKORAS-101 and BREAKER-101 clinical trials, and the expected dosing of the first patient with BBO-11818, with potential for regulatory approval of its product candidates.

Industry Context

This announcement reflects the ongoing trend of Special Purpose Acquisition Company (SPAC) mergers, particularly in the biotechnology and pharmaceutical sectors, as a mechanism for private companies like BridgeBio Oncology Therapeutics to go public. The focus on RAS and PI3K malignancies aligns with a significant area of oncology research and development, targeting highly prevalent cancer-driving oncogenes.

Stakeholder Impact

• Shareholders of Helix will vote on the business combination and receive the Proxy Statement/Prospectus. Their investment will transition to shares in the combined entity (PubCo) if the merger closes.
• Shareholders of BBOT will have their ownership converted into shares of PubCo.
• The progress of BBOT's clinical pipeline (ONKORAS-101, BREAKER-101, BBO-11818) could lead to new therapeutic options for patients with RAS and PI3K malignancies.

Next Steps

• Mailing of the definitive Proxy Statement/Prospectus to Helix shareholders of record as of June 30, 2025.
• Extraordinary General Meeting of Helix shareholders on August 4, 2025, to vote on the Business Combination.
• Anticipated closing of the Business Combination in August 2025.
• Upon closing, the company will be renamed BridgeBio Oncology Therapeutics (PubCo).
• Continued product development activities for BBOT's product candidates, including ONKORAS-101, BREAKER-101 clinical trials, and dosing of the first patient with BBO-11818.

Key Dates

Recommendation

Keywords

SPAC, Business Combination, Merger, Biopharmaceutical, Oncology, RAS malignancies, PI3K malignancies, Clinical-stage, SEC filing, Form S-4, Proxy Statement, Shareholder Vote, Helix Acquisition Corp. II, BridgeBio Oncology Therapeutics, Cormorant Asset Management, HLXB